Milestone Pharmaceuticals Announces Proposed Public Offering
Milestone Pharmaceuticals (NASDAQ: MIST) has announced a proposed public offering of common shares along with Series A and Series B warrants. The company is also offering pre-funded warrants as an alternative to common shares for certain investors.
The proceeds will be used to fund the clinical development and commercial launch of etripamil for paroxysmal supraventricular tachycardia (PSVT), along with working capital and general corporate purposes. The offering is being managed by TD Cowen, Piper Sandler & Co., and Wells Fargo Securities as joint book-running managers, with H.C. Wainwright & Co. as lead manager.
Milestone Pharmaceuticals (NASDAQ: MIST) ha annunciato un'offerta pubblica proposta di azioni ordinarie insieme a warrant di Serie A e Serie B. L'azienda offre anche warrant pre-finanziati come alternativa alle azioni ordinarie per alcuni investitori.
I proventi saranno utilizzati per finanziare lo sviluppo clinico e il lancio commerciale di etripamil per la tachicardia sopraventricolare parossistica (PSVT), oltre a capitale operativo e scopi aziendali generali. L'offerta 猫 gestita da TD Cowen, Piper Sandler & Co. e Wells Fargo Securities come joint book-running manager, con H.C. Wainwright & Co. come lead manager.
Milestone Pharmaceuticals (NASDAQ: MIST) ha anunciado una oferta p煤blica propuesta de acciones comunes junto con warrants Serie A y Serie B. La compa帽铆a tambi茅n ofrece warrants prefinanciados como alternativa a las acciones comunes para ciertos inversores.
Los ingresos se utilizar谩n para financiar el desarrollo cl铆nico y el lanzamiento comercial de etripamil para la taquicardia supraventricular parox铆stica (PSVT), junto con capital de trabajo y prop贸sitos corporativos generales. La oferta est谩 siendo gestionada por TD Cowen, Piper Sandler & Co. y Wells Fargo Securities como gestores conjuntos, con H.C. Wainwright & Co. como gestor principal.
Milestone Pharmaceuticals (NASDAQ: MIST)電� 氤错喌欤检檧 頃粯 鞁滊Μ歃� A 氚� 鞁滊Μ歃� B 鞗岆煱韸�鞚� 瓿店皽 氚滍枆鞚� 鞝滌晥頄堨姷雼堧嫟. 須岇偓電� 韸轨爼 韴瀽鞛愲ゼ 鞙勴暣 氤错喌欤� 雽�鞁� 靷毄頃� 靾� 鞛堧姅 靹犾旮� 鞗岆煱韸鸽弰 鞝滉车頃╇媹雼�.
靾橃澋旮堨潃 氚滌瀾靹� 靸侅嫭鞁れ劚 牍堧Д(PSVT) 旃橂鞝滌澑 鞐愴姼毽寣氚�鞚� 鞛勳儊 臧滊皽 氚� 靸侅梾鞝� 於滌嫓 鞛愱笀瓿� 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅� 鞓堨爼鞛呺媹雼�. 鞚措矆 瓿惦電� TD Cowen, Piper Sandler & Co., Wells Fargo Securities臧� 瓿惦彊 欤缄皠靷 甏�毽晿氅�, H.C. Wainwright & Co.臧� 雽�響� 欤缄皠靷 彀胳棳頃╇媹雼�.
Milestone Pharmaceuticals (NASDAQ : MIST) a annonc茅 une offre publique propos茅e d'actions ordinaires accompagn茅e de bons de souscription de s茅rie A et s茅rie B. La soci茅t茅 propose 茅galement des bons de souscription pr茅financ茅s comme alternative aux actions ordinaires pour certains investisseurs.
Les fonds seront utilis茅s pour financer le d茅veloppement clinique et le lancement commercial d'etripamil pour la tachycardie supraventriculaire paroxystique (PSVT), ainsi que le fonds de roulement et des besoins g茅n茅raux d'entreprise. L'offre est g茅r茅e par TD Cowen, Piper Sandler & Co. et Wells Fargo Securities en tant que gestionnaires conjoints, avec H.C. Wainwright & Co. en tant que gestionnaire principal.
Milestone Pharmaceuticals (NASDAQ: MIST) hat ein geplantes 枚ffentliches Angebot von Stammaktien zusammen mit Warrants der Serie A und Serie B angek眉ndigt. Das Unternehmen bietet bestimmten Investoren au脽erdem vorfinanzierte Warrants als Alternative zu Stammaktien an.
Die Erl枚se werden zur Finanzierung der klinischen Entwicklung und des kommerziellen Starts von Etripamil bei paroxysmaler supraventrikul盲rer Tachykardie (PSVT) sowie f眉r Betriebskapital und allgemeine Unternehmenszwecke verwendet. Das Angebot wird von TD Cowen, Piper Sandler & Co. und Wells Fargo Securities als gemeinsame Bookrunner verwaltet, wobei H.C. Wainwright & Co. als Lead Manager fungiert.
- None.
- Potential dilution for existing shareholders
- Offering size and terms not yet determined
- Market conditions may affect offering completion
Insights
Milestone's public offering will dilute shares but provides crucial funding for etripamil's commercialization, indicating final development stages.
This public offering announcement signals a significant capital raising event for Milestone Pharmaceuticals that will impact existing shareholders through dilution. The company is offering common shares along with Series A and Series B warrants, plus pre-funded warrants for certain investors, all indicators of a substantial financing round.
The offering's primary purpose is funding the clinical development and commercial launch of etripamil for paroxysmal supraventricular tachycardia (PSVT), which represents the company's lead program. This suggests Milestone is approaching the final stages of development and preparing for commercialization, a capital-intensive phase requiring significant investment for market entry.
The involvement of multiple investment banks as joint book-running managers (TD Cowen, Piper Sandler, and Wells Fargo Securities) with H.C. Wainwright as lead manager indicates this is a substantial offering with strong institutional backing. The structure using both common shares and warrants provides the company flexibility while potentially offering investors additional incentives through the warrant components.
While this financing will provide necessary capital for Milestone's commercialization efforts, investors should recognize this offering will likely cause share dilution, potentially pressuring the stock price in the near term. However, the proceeds may significantly extend the company's operational runway, potentially through the critical commercialization phase for etripamil in PSVT.
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone庐 Pharmaceuticals Inc. (鈥淢ilestone鈥�) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the 鈥淥ffering鈥�) of its common shares, accompanying听Series A warrants to purchase common shares (the 鈥淪eries A Warrants鈥�) and accompanying Series B warrants to purchase common shares (the 鈥淪eries B Warrants鈥�), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, accompanying Series A Warrants and accompanying Series B warrants. All securities to be sold in the Offering will be sold by Milestone. The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Milestone intends to use the net proceeds from the Offering, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead indication of paroxysmal supraventricular tachycardia (PSVT), as well as for working capital and other general corporate purposes.
TD Cowen, Piper Sandler & Co. and Wells Fargo Securities are acting as joint book-running managers for the Offering. H.C. Wainwright & Co. is acting as lead manager for the Offering.
The securities described above are being offered by Milestone pursuant to a shelf registration statement on Form S-3 (File No. 333-283162), including a base prospectus, that was declared effective by the U.S. Securities and Exchange Commission (the 鈥淪EC鈥�) on November 22, 2024. The Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the Offering will be filed with the SEC and will be available on the SEC鈥檚 website located at www.sec.gov. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may also be obtained, when available, from: TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at 855-495-9846, or by email at ; Piper Sandler, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by email at ; and Wells Fargo Securities, LLC, 90 South 7th Street, 5th Floor, Minneapolis, MN 55402, or by telephone at 800-645-3751 (option #5), or by email at .
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Milestone Pharmaceuticals听
Milestone Pharmaceuticals Inc.鈥�(Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渄emonstrate,鈥� 鈥渄esigned,鈥� 鈥渄evelop,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渕ay,鈥� 鈥減ending,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減rogress,鈥� 鈥渨ill鈥�, 鈥渋ntend鈥� and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone鈥檚 expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements, among others, regarding: the proposed Offering, including the anticipated terms of the Offering and the completion of the Offering on the anticipated terms, or at all, and Milestone鈥檚 intended use of proceeds from the Offering, if any. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, market and other financial conditions; satisfaction of customary closing conditions related to the Offering; whether our future interactions with the FDA, including with regard of the new drug application for etripamil for PSVT, will have satisfactory outcomes; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone鈥檚 capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone鈥檚 filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2024 and its quarterly report on Form 10-Q for the three months ended March 31, 2025, in each case under the caption 鈥淩isk Factors,鈥� as such discussion may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.听
Contact
Investor Relations
Kevin Gardner, [email protected]
FAQ
What is the purpose of Milestone Pharmaceuticals (MIST) public offering in July 2025?
What types of securities is MIST offering in this public offering?
Who are the underwriters for Milestone Pharmaceuticals' 2025 offering?
What is etripamil and what is it being developed for by Milestone Pharmaceuticals?
How will this offering affect existing MIST shareholders?
